The Cardiovascular Plot Twist Nobody Expected
When you start talking about semaglutide or tirzepatide, the conversation usually lands on weight loss numbers. But here’s where it gets interesting. Recent research out of the SELECT trial published in the New England Journal of Medicine found that semaglutide reduced cardiovascular events by approximately one-fifth in non-diabetic adults with obesity. That’s not a rounding error. That’s a meaningful reduction in heart attacks and strokes, independent of how much weight someone actually lost.
What does this mean for you in year two? Your body is likely experiencing systemic changes that go way beyond what the scale tells you. The medications work on multiple pathways at once. Your cardiovascular system isn’t just benefiting from weight loss alone. The medication itself appears to have direct protective effects on your heart and blood vessels. You can read more about these findings in the NEJM SELECT Trial Results on Semaglutide and Cardiovascular Risk.
Tirzepatide’s Rise and What That Tells Us About Real-World Outcomes
Tirzepatide, marketed as Mounjaro, received FDA approval for chronic weight management in late 2023. By 2025, it’s now the most prescribed branded medication in its entire class across the United States. That’s not because of marketing hype. People are experiencing results, and they’re talking about them. When millions of prescriptions happen, the collective experience matters.
The FDA approval data showed strong efficacy, but real-world use has revealed something else entirely. Women specifically have been reporting that the medication works differently for them than the clinical trial data predicted. You can explore the approval details in the FDA Tirzepatide Approval Information. But the lived experience story is being written by people like you, right now, in year two of treatment.
The Muscle Loss Reality (And How to Actually Address It)
Here’s the number that should make you sit up and pay attention. Research published in Nature Medicine in 2025 found that approximately 40 percent of weight lost on GLP-1 medications includes lean muscle mass. That’s not a small portion. That’s nearly half of your weight loss potentially coming from muscle tissue rather than fat. And this happens without conscious resistance training intervention.
This data completely changed how bariatric surgery specialists approach these medications. The American Society for Metabolic and Bariatric Surgery documented a 28 percent increase in patients specifically asking about muscle preservation protocols because of GLP-1 concerns. Women are walking into their appointments with real questions now. They’re asking about resistance training, protein targets, thinking more carefully about their health outcomes instead of just waiting to see what happens.
The practical implication for year two? If you haven’t prioritized strength training yet, this is your signal. You don’t need to become a bodybuilder. Two to three sessions per week of resistance work, combined with hitting protein targets (generally 0.7 to 1.0 grams per pound of your goal body weight), meaningfully changes what your weight loss actually represents. You’re shifting the ratio of fat loss to muscle preservation in your favor.
The Unexpected Psychological Shifts Nobody Warns You About
Let’s talk about what actually surprised people in year two. Patient-reported outcomes in Obesity Reviews showed that 61 percent of women on semaglutide for 12 months or longer reported unexpected changes in alcohol cravings and food noise reduction. Sixty-one percent. That’s not an outlier experience. That’s the dominant experience.
Food noise is that constant mental chatter about what you’ll eat next, whether you’re hungry, what’s in the kitchen. For many women, it never stops. Until it does. And then it’s genuinely disorienting. Some describe it as the first time they’ve experienced silence in their heads in decades. Others find it unsettling. Some people report that alcohol simply doesn’t appeal to them anymore. A glass of wine they used to enjoy feels completely uninteresting.
These changes matter for year two because you might be navigating social situations differently. You might have more mental space for other things. You might need to rethink how you relate to food around holidays or celebrations. This isn’t inherently good or bad. It’s just real, and it deserves attention.
Thinking Probabilistically About Your Own Outcomes
Here’s the honest truth about the second year on these medications. The data shows general patterns, but your body will write its own story. Twenty percent cardiovascular risk reduction sounds great in population terms, but it means something specific for your individual risk profile. Forty percent muscle loss in weight loss is a statistical reality, but it depends entirely on whether you’re doing resistance training. Sixty-one percent experiencing food noise reduction is meaningful, but that also means 39 percent don’t.
The invitation for you in year two is to stop thinking about these medications in binary terms, whether they work or they don’t, and start thinking statistically. What’s your actual adherence? Are you doing the resistance training? What does your protein intake look like? How is your cardiovascular health actually trending? Are the psychological shifts beneficial for you or something to work through with professional support?
This is where individualized medicine happens. You have access to more data and more research than ever before. Your doctor has more information. And you have the lived experience nobody else can contribute to your care plan. Year two is where the real optimization happens, where you stop just taking the medication and start actively participating in what that medication is actually doing to and for your body. That’s where the conversation gets interesting.